What is it about?
Prevalence estimation of an underutilized therapy in stabilizing prostate cancer patients under hormonal therapy, which is the intermittent androgen deprivation (IAD) therapy. This consists in stopping continuous treatment meanwhile the pathology is in standby (PSA is maintained and there are not clinical signs of progress). In this extensive study carried out in 4 Spanish Autonomous Communities (36% of Spanish population) and more than 65000 patients, we estimated that the use of IAD is lower than 7%.
Featured Image
Photo by JD Mason on Unsplash
Why is it important?
A significant proportion of prostate cancer patients without clinical signs of progress are currently overtreated in Spain.
Perspectives
The same methodology could be applied in other countries where growing evidence suggest that IAD is also underutilized.
Dr. José Antonio Cordero
Fundacio Blanquerna Universitat Ramon Llull
Read the Original
This page is a summary of: Prevalence study of intermittent hormonal therapy of Prostate Cancer patients in Spain, F1000Research, October 2021, Faculty of 1000, Ltd.,
DOI: 10.12688/f1000research.53875.1.
You can read the full text:
Contributors
The following have contributed to this page
